Quantrx Biomedical (Quantrx Biomedical) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2022)

View and export this data going back to . Start your Free Trial

What is Quantrx Biomedical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Quantrx Biomedical's long-term debt to total assests ratio for the quarter that ended in Sep. 2022 was 0.00.

Quantrx Biomedical's long-term debt to total assets ratio stayed the same from Sep. 2021 (0.00) to Sep. 2022 (0.00).

Quantrx Biomedical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Quantrx Biomedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantrx Biomedical LT-Debt-to-Total-Asset Chart

Quantrx Biomedical Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Quantrx Biomedical Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Quantrx Biomedical LT-Debt-to-Total-Asset Calculation

Quantrx Biomedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )	/	Total Assets (A: Dec. 2021 )
	=	0	/	0.006
	=

Quantrx Biomedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

LT Debt to Total Assets (Q: Sep. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2022 )	/	Total Assets (Q: Sep. 2022 )
	=	0	/	0.005
	=

Quantrx Biomedical (OTCPK:QTXB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Quantrx Biomedical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Quantrx Biomedical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantrx Biomedical (Quantrx Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quantrx Biomedical Corp (OTCPK:QTXB) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

10190 SW 90th Avenue, Tualatin, OR, USA, 97062

Website

http://www.quantrx.com

Quantrx Biomedical Corp operates towards the development and commercialization of patented mini form pad (PAD) based products. The PAD products are based on the company's non-woven disposable absorbent pad technology and it is involved in the PAD-based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its platforms include inSync(R), Unique(TM), and OEM branded over-the-counter and laboratory testing products.

Executives

Michael S Abrams	director	64 RAMSHEAD ROAD, RAYNHAM MA 02767
Patrick T Mooney	director	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Robert G. Pinco	director	1700 K STREET NW, SUITE 300, WASHINGTON DC 20006
Hayes Arthur H Jr	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Matthew Balk	10 percent owner	229 WEST 60TH STREET, NEW YORK NY 10023
Evan Levine	director, 10 percent owner	1517 SAN JACINTO ST., HOUSTON TX 77002
Hayes Arthur Hull Jr	director	C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901
Cindy Horton	officer: V.P. of Diagnostics	209 BRITTANY PARK, ANDERSON SC 29621
Sasha Afanassiev	officer: Officer	120 GARRISON COURT, LANGHORNE PA 19047
Shalom Hirschman	officer: Officer	5240 BLACKSTONE AVENUE, RIVERDALE NY 10471
William H Fleming	director, officer: Secretary
Walter W Witoshkin	director, officer: President and CEO	321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002
Mark Capital Llc	10 percent owner	5173 SEAGROVE PLACE, SAN DIEGO CA 92130
Sherbrooke Partners, Llc	10 percent owner	570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282

Quantrx Biomedical (Quantrx Biomedical) Headlines

No Headlines